TNF Pharmaceuticals (TNFA, Financial) has entered a strategic partnership with Renova Health to advance the development of isomyosamine, a drug designed to help maintain muscle mass during GLP-1 treatment, through the use of artificial intelligence and machine learning.
This collaboration will harness data from 30,000 patients to streamline recruitment and expedite the development process of isomyosamine. Renova Health's sophisticated platform is instrumental in identifying specific patient subsets based on various factors, such as underlying health conditions, acute medical events, and existing medication profiles.
